ALLGF News and Press, Alligator Bioscience AB From 09/16/20

The USPTO has issued Alligator Bioscience ( OTC:ALLGF ) a Patent No. 10,774,150, which covers compositions of matter directed to the company's bispecific drug candidate ATOR-1015. The granted patent's earliest expiry year is 2036. More news on: Alligator Bioscience AB (publ), Heal...

LUND, Sweden , Sept. 16, 2020 /PRNewswire/ -- Alligator Bioscience (Nasdaq Stockholm: ATORX)  announced today that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 10,774,150 which covers compositions of matter directed to Alligator's bispecific drug ...

LUND, Sweden , Sept. 4, 2020 /PRNewswire/ -- Alligator Bioscience (Nasdaq Stockholm: ATORX)  announced today biomarker data from a recently performed clinical Phase I study of the drug candidate mitazalimab, its wholly owned CD40 antibody in development primarily for the treatment o...

LUND, Sweden , Aug. 27, 2020 /PRNewswire/ -- Alligator Bioscience (Nasdaq Stockholm: ATORX)  announced today interim safety data from its ongoing clinical Phase I study of the drug candidate ATOR-1017, its wholly owned 4-1BB antibody in development for the treatment of metastasized ...

LUND, Sweden , Aug. 25, 2020 /PRNewswire/ -- Alligator Bioscience (Nasdaq Stockholm: ATORX) will give status updates and details on the recent clinical development plans for the clinical drug candidates mitazalimab, ATOR-1015 and ATOR-1017 on a virtual R&D Day on August 27 . "The...

Alligator Bioscience ( OTC:ALLGF ): Q2 GAAP EPS of -SEK0.49. More news on: Alligator Bioscience AB (publ), Earnings news and commentary, , Read more ...

STOCKHOLM , July 13, 2020 /PRNewswire/ -- Promising safety data for ATOR-1015 " With the new strategy announced in early April, we have put a stronger focus on Alligator's clinical development portfolio. ATOR-1015 has received a great deal of attention in connection with the pos...

SEATTLE and LUND, Sweden , June 10, 2020 /PRNewswire/ -- Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ bispecific technology platform, and Alligator Bioscience AB (N...

LUND, Sweden , June 4, 2020 /PRNewswire/ -- Alligator Bioscience (Nasdaq Stockholm: ATORX) and Scandion Oncology (Spotlight, Sweden: SCOL), today announced signing of a collaboration agreement. The two companies have agreed to explore the anti-tumor efficacy of the CD40 antibody mitazal...

LUND, Sweden , June 1, 2020 /PRNewswire/ -- Alligator Bioscience (Nasdaq Stockholm: ATORX), today announces that the company received an additional USD 0.5 million in a second installment of the upfront payment from the Chinese company Biotheus Inc. A first installment of USD 0.5 mil...